شنبه 1 دی 1403
[Archive]
دوره 29، شماره 133 - ( 11-1399 )
جلد 29 شماره 133 صفحات 117-109 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rostami S, Kazemi A, Chahardouli B, Mohammadi S, Nikbakht M, Alizadeh N, et al . The Prognostic Impact of WT1 Expression Levels, Mutations, and SNP rs16754 in AML Patients: A Retrospective Cohort Study. J Adv Med Biomed Res 2021; 29 (133) :109-117
URL: http://journal.zums.ac.ir/article-1-6130-fa.html
URL: http://journal.zums.ac.ir/article-1-6130-fa.html
The Prognostic Impact of WT1 Expression Levels, Mutations, and SNP rs16754 in AML Patients: A Retrospective Cohort Study. Journal of Advances in Medical and Biomedical Research. 1399; 29 (133) :109-117
چکیده: (143319 مشاهده)
Background and Objective: The clinical outcomes and treatment options for acute myeloid leukemia (AML) patients are highly dependent upon molecular markers. In this study, Wilms tumor (WT1) (exons 7 and 9) mutations, SNP rs16754, and WT1 expression levels in 130 random AML patients were screened; FMs-like tyrosine kinase-3 internal tandem duplication (FLT3-ITD), nucleophosmin (NPM1), and CCAAT/enhancer-binding protein alpha (CEBPA) mutations were also evaluated.
Material and Methods: Overall, 130 AML patients were recruited for our study. WT1 mutations were determined by Sanger sequencing, and expression levels were determined by real-time PCR. The Kaplan-Meier method was used to calculate overall survival (OS) and disease-free survival (DFS).
Results: The frequency of WT1 mutations in the study population was 5.4%, and it did not affect overall survival (OS) (p=0.98), disease-free survival (DFS) (p=0.97), or complete remission (CR) rates in AML patients. The major allele of SNP rs16754 in the current study was A. No significant differences were found for OS (p=0.52), DFS (p=0.42), or complete remission rates among all SNP rs16754 genotypes. The overexpression of WT1 was observed in 83% of patients at diagnosis. No significant difference was found for OS (p=0.84), DFS (p=0.82), or complete remission rates between AML patients with high and low WT1 expression levels.
Conclusion: The results of the current study do not support WT1 mutation, SNP rs16754, or WT1 overexpression at diagnosis, as they were found to be poor prognostic markers in AML patients.
نوع مطالعه: مقاله پژوهشی |
موضوع مقاله:
Clinical medicine
دریافت: 1399/4/29 | پذیرش: 1399/7/3 | انتشار: 1399/9/14
دریافت: 1399/4/29 | پذیرش: 1399/7/3 | انتشار: 1399/9/14
فهرست منابع
1. References:
2. Ardestani MT, Kazemi A, Chahardouli B, et al. FLT3-ITD compared with DNMT3A R882 mutation is a more powerful independent inferior prognostic factor in adult acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation: a retrospective cohort study. Turkish J Hematol. 2018;35(3):158. [DOI:10.4274/tjh.2018.0017]
3. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. New Eng J Med. 2015;373(12):1136-52. [DOI:10.1056/NEJMra1406184]
4. King-Underwood L, Renshaw J, Pritchard-Jones K. Mutations in the Wilms' tumor gene WT1 in leukemias. Blood. 1996;87(6):2171-9. [DOI:10.1182/blood.V87.6.2171.bloodjournal8762171]
5. Andersson C, Li X, Lorenz F, Golovleva I, Wahlin A, Li A. Reduction in WT1 gene expression during early treatment predicts the outcome in patients with acute myeloid leukemia. Diag Molec Pathol. 2012;21(4):225-33. [DOI:10.1097/PDM.0b013e318257ddb9]
6. Luo S, Yu K, Yan Qx, et al. Analysis of WT1 mutations, expression levels and single nucleotide polymorphism rs16754 in de novo non-M3 acute myeloid leukemia. Leukemia & lymphoma. 2014;55(2):349-57. [DOI:10.3109/10428194.2013.791985]
7. Hou HA, Huang TC, Lin LI, et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood. 2010;115(25):5222-31. [DOI:10.1182/blood-2009-12-259390]
8. Rampal R, Figueroa ME. Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia. Haematologica. 2016;101(6):672-9. [DOI:10.3324/haematol.2015.141796]
9. Gaidzik VI, Schlenk RF, Moschny S, et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood. 2009;113(19):4505-11. [DOI:10.1182/blood-2008-10-183392]
10. Choi Y, Lee JH, Hur EH, et al. Single nucleotide polymorphism of Wilms' tumor 1 gene rs16754 in Korean patients with cytogenetically normal acute myeloid leukemia. Ann Hematol. 2012;91(5):671-7. [DOI:10.1007/s00277-011-1355-4]
11. Benthaus T, Schneider F, Mellert G, et al. Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia. Br J Haematol. 2008;143(2):230-9. [DOI:10.1111/j.1365-2141.2008.07328.x]
12. Ghasemi A, Nadali F, Chahardouli B, Ghandforosh NA, Zadeh AG, Rostami S. Study of correlation between SFRP-1 and SFRP-2 hypermethylation with relapse, complete remission, genetic mutations of FLT3-ITD and NPM1 and immunophenotypes of leukemic cells in patients with de novo acute myeloblastic leukemia. J Hematol. 2014;3(2):34-42. [DOI:10.14740/jh154w]
13. Toogeh G, Ramzi M, Faranoush M, et al. Prevalence and prognostic impact of Wilms' tumor 1 (WT1) gene, including SNP rs16754 in cytogenetically normal acute myeloblastic leukemia (CN-AML): An Iranian experience. Clin Lymphoma Myeloma Leuk. 2016;16(3):e21-e6. [DOI:10.1016/j.clml.2015.11.017]
14. Mitelman IF. Guidelines for Cancer Cytogenetics supplement to an International System for Human Genetics nomenclature. Basel: S. Karger; 1995.
15. Tien FM, Hou HA, Tang JL, et al. Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant CEBPA. Haematologica. 2018;103(11):e510-e3. [DOI:10.3324/haematol.2018.189043]
16. Xu J, Zhang Y, Hu J, Ren Y, Wang H. Clinical features and prognosis of normal karyotype acute myeloid leukemia pediatric patients with WT1 mutations: an analysis based on TCGA database. Hematol. 2020;25(1):79-84. [DOI:10.1080/16078454.2020.1720102]
17. Niktoreh N, Walter C, Zimmermann M, et al. Mutated WT1, FLT3-ITD, and NUP98-NSD1 fusion in various combinations define a poor prognostic group in pediatric acute myeloid leukemia. J Oncol. 2019;2019. [DOI:10.1155/2019/1609128]
18. Tanwar P, Haider I, Bakhshi S, Kumar L. Prospective evaluation for mutational frequency of Wilm's Tumor-1 (WT1) gene in De Novo cases of acute myeloid leukaemia. Clin Lymphoma, Myeloma Leuk. 2018;18:S197 [DOI:10.1016/j.clml.2018.07.042]
19. Damm F, Heuser M, Morgan M, et al. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2009;28(4):578-85. [DOI:10.1200/JCO.2009.23.0342]
20. Hollink I, van den Heuvel-Eibrink MM, Zimmermann M, et al. No prognostic impact of the WT1 gene single nucleotide polymorphism rs16754 in pediatric acute myeloid leukemia. J Clin Oncol. 2010;28(28):e523-6. [DOI:10.1200/JCO.2010.29.3860]
21. Petiti J, Rosso V, Iacono ML, et al. Prognostic significance of the Wilms' tumor-1 (WT1) rs16754 polymorphism in acute myeloid leukemia. Leukemia Res. 2018;67:6-11. [DOI:10.1016/j.leukres.2018.01.016]
22. Ramzi M, Moghadam M, Cohan N. Wilms Tumor-1 (WT1) rs16754 polymorphism and clinical outcome in acute myeloid leukemia. Turk J Haematol. 2019;36(1):67-8. [DOI:10.4274/tjh.galenos.2018.2018.0277]
23. Østergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients-results from a single‐centre study. Br J Haematol. 2004;125(5):590-600. [DOI:10.1111/j.1365-2141.2004.04952.x]
24. Lyu X, Xin Y, Mi R, et al. Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia. PloS one. 2014;9(3):e92470. [DOI:10.1371/journal.pone.0092470]
25. Nomdedéu JF, Esquirol A, Carricondo M, et al. Bone marrow WT1 levels in allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplasia: clinically relevant time points and 100 copies threshold value. Biol Blood Marrow Transplant. 2018;24(1):55-63. [DOI:10.1016/j.bbmt.2017.09.001]
26. Dongfen D, Lixia Z, Yungui W, XiujinG Y. Expression of WT1 gene and its prognostic value in patients with acute myeloid leukemia. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2019;48(1):50-57.
27. Mitrovic M, Kostic T, Virijevic M, et al. The influence of Wilms' tumor 1 gene expression level on prognosis and risk stratification of acute promyelocytic leukemia patients. Int J Lab Hematol. 2020;42(1):82-7. [DOI:10.1111/ijlh.13144]
28. Ebtesam A,El-Akad GM, Ismail WI, Al Nagar AA. Study of Wilms' tumor 1 gene expression in patients with acute myeloid leukemia. Egypt J Haematol. 2019;44(4):195. [DOI:10.4103/ejh.ejh_26_19]
29. Shimada A, Taki T, Koga D, et al. High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group. Int J Hematol. 2012;96(4):469-76. [DOI:10.1007/s12185-012-1163-1]
30. Gaur GC, Ramadan SM, Cicconi L, et al. Analysis of mutational status, SNP rs16754, and expression levels of Wilms tumor 1 (WT1) gene in acute promyelocytic leukemia. Ann Hematol. 2012;91(12):1855-60. [DOI:10.1007/s00277-012-1546-7]
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
